"Fenway Health's Ansin Building at 1340 Boylston St. is your one-stop shop for full-service medical, behavioral health, dental and eye care. We also have a full-service pharmacy and offer a variety of services from HIV and STD testing to complementary therapies, LGBT parenting services, a Violence Recovery Program and women’s health and transgender health services. For your convenience, we offer extended hours in the evenings and on Saturdays. For more information: Appointments - 617.267.0900 Pharmacy Refill Line - 617.927.6330 Medical Referral Fax - 617.267.0900"

During the past decade, The Fenway Institute conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 7 clinical trials were completed, i.e. on average, 35% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 5 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Fenway Institute" #1 sponsor was "University of North Carolina, Chapel Hill" with 12 trials, followed by "Genocea Biosciences, Inc." with 4 trials sponsored, "Fenway Community Health" with 3 trials sponsored, "Massachusetts General Hospital" with 2 trials sponsored and "National Institute of Allergy and Infectious Diseases (NIAID)" with 2 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Fenway Institute" #1 collaborator was "National Institute of Mental Health (NIMH)" with 16 trials as a collaborator, "National Institute on Drug Abuse (NIDA)" with 9 trials as a collaborator, "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 5 trials as a collaborator, "The Fenway Institute" with 4 trials as a collaborator and "Emory University" with 3 trials as a collaborator. Other collaborators include 23 different institutions and companies that were collaborators in the rest 29 trials.

According to Clinical.Site data, the most researched conditions in "The Fenway Institute" are "HIV Infection" (7 trials), "HIV" (5 trials), "Genital Herpes Simplex Type 2" (4 trials), "HIV/AIDS" (2 trials) and "Medication Adherence" (2 trials). Many other conditions were trialed in "The Fenway Institute" in a lesser frequency.

Most popular intervention types in "The Fenway Institute" are "Behavioral" (16 trials), "Drug" (10 trials), "Biological" (4 trials), "Other" (3 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "CBT-based counseling" (2 trials), "Emtricitabine/tenofovir (FTC/TDF (Truvada®))" (2 trials), "GEN-003 Vaccine (30μg of each antigen)" (2 trials) and "GEN-003 Vaccine (60μg of each antigen)" (2 trials). Other intervention names were less common.

The vast majority of trials in "The Fenway Institute" are 18 trials for "All" genders, 15 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "The Fenway Institute". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 28 completed trials in The Fenway Institute, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in The Fenway Institute, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 14 trials that are defined as “Not Applicable".